0.00
—
Close of 30 Oct 2026, in USD
About Viropro
Its shares trade under the ticker VPRO. It has been listed since 21 June 2001. In the fiscal year to 31 December 2010, it reported revenue of $571,098 and a net loss of $1.0m. At that date it held total assets of $2.1m and shareholders' equity of $1.5m.
Viropro, Inc. engages in the development, manufacture and sale of biopharmaceutical products. The company is headquartered in Irvine, California. The company went IPO on 2001-06-21. The firm conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The firm intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 21 Jun 2001
- Employees
- 34
- Website
- viropro.net/defaultsite ↗
Leadership
Pay as last reported
- Mr. Bruce CohenInterim Chairman of the Board, since 2014
- Jeffrey HaleChief Business Officer, since 2010
- Ms. Michelle PeakeDirector
- Dr. Ann RoseDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Viropro Inc possesses several strengths that contribute to its success. Firstly, the company has a highly experienced and talented workforce with a deep understanding of the biotechnology industry. This expertise enables Viropro to develop and manufacture innovative pharmaceutical products.
- Secondly, Viropro Inc benefits from strong research and development capabilities, allowing them to stay at the forefront of medical advancements. The company invests extensively in exploring new technologies and improving existing ones, ensuring they remain competitive in the market.
- Furthermore, Viropro Inc has established strategic partnerships with key industry players and healthcare institutions. These collaborations enhance their ability to access resources, share knowledge, and tap into new markets, bolstering their overall growth potential.
Weaknesses
- Despite Viropro Inc's strengths, there are some weaknesses that can hinder its progress. One weakness is the company's heavy dependence on a limited number of revenue streams. This lack of diversification leaves them vulnerable to market fluctuations or external factors that may impact those specific revenue streams.
- Additionally, Viropro Inc struggles with a relatively small market share compared to some of its larger competitors. This can limit their market influence and bargaining power, making it challenging to negotiate favorable terms with suppliers or customers.
- Moreover, Viropro Inc faces potential challenges related to regulatory compliance. With strict regulations and quality standards governing the pharmaceutical industry, any non-compliance issues may result in significant financial and reputational damages.
Opportunities
- Viropro Inc has several opportunities for growth and expansion. Firstly, the increasing demand for advanced medical treatments presents a significant opportunity for the company to capitalize on. By leveraging their expertise in biotechnology, Viropro can develop new therapies to meet this rising demand.
- Additionally, the company can explore strategic alliances or acquisitions to gain access to new markets or technologies. Collaborating with emerging biotech startups or acquiring innovative patents can help Viropro diversify its product portfolio and capture untapped market potential.
- Furthermore, Viropro Inc can leverage digital advancements to enhance its operations and improve patient outcomes. By investing in technologies such as data analytics and telemedicine, the company can streamline processes, reduce costs, and deliver personalized healthcare solutions.
Threats
- Viropro Inc must also address potential threats that could impact its business. Firstly, intense competition within the biotechnology industry poses a threat to market share and profitability. Rival companies with similar capabilities and resources may develop competing products or offer them at more competitive prices.
- Moreover, changes in government regulations or healthcare policies can have a significant impact on Viropro Inc's operations. Compliance with evolving regulations and adapting to new policies may require additional resources and could potentially disrupt their business model.
- Lastly, economic downturns or shifts in global financial markets can affect Viropro Inc's access to funding or investment opportunities. Reduced investor confidence or restricted access to capital can hinder their ability to finance research and development initiatives or expand their market presence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.